Reply to C. Kersten et al and D.A. Parikh et al

J Clin Oncol. 2019 Jun 20;37(18):1592-1593. doi: 10.1200/JCO.18.02369. Epub 2019 May 2.

Authors

Shukui Qin¹, Tianshu Liu¹, Jin Li¹

Affiliation

¹ Shukui Qin, MD, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China; Tianshu Liu, MD, Zhongshan Hospital, Shanghai, People's Republic of China; and Jin Li, MD, Fudan University Cancer Hospital and Tongji University East Hospital, Shanghai, People's Republic of China.

PMID: 31046552
DOI: 10.1200/JCO.18.02369

No abstract available

Publication types

Letter
Comment

MeSH terms

Cetuximab
Fluorouracil
Humans
Leucovorin
Oxaliplatin*
Rectal Neoplasms*

Substances

Oxaliplatin
Cetuximab
Leucovorin
Fluorouracil